STOCK TITAN
  1. Home
  2. Sec-filings
  3. MMED
  4. [Form 4] MiniMed Group, Inc. Insider Trading Activity

MiniMed Group (MMED) officer receives 15,322-share RSU grant after separation

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MiniMed Group, Inc. officer John Gyurci reported receiving 15,322 shares of common stock on a grant or award basis, with no cash price per share. These shares represent restricted stock units in MiniMed that were created by converting prior Medtronic equity awards in connection with MiniMed’s separation from Medtronic.

The units were granted under the 2026 MiniMed Group, Inc. Long Term Incentive Plan and vest in three equal installments on January 26, 2027, January 26, 2028, and January 26, 2029. Following this equity award conversion, Gyurci directly holds 15,322 MiniMed shares, including shares to be issued upon future vesting of restricted stock units.

Positive

  • None.

Negative

  • None.
Insider Gyurci John
Role See Remarks
Type Security Shares Price Value
Grant/Award Common Stock 15,322 $0.00 --
Holdings After Transaction: Common Stock — 15,322 shares (Direct)
Footnotes (1)
  1. In connection with MMED's separation from Medtronic plc ("Medtronic") effective March 9, 2026 (the "Separation"), as further described in MMED's current report on Form 8-K filed on March 9, 2026, certain restricted stock units and performance share units granted by Medtronic held by the Reporting Person (the "Medtronic Awards") were converted into time-vesting restricted stock units denominated in shares of MMED's common stock ("MMED RSUs") pursuant to the terms of the Employee Matters Agreement, dated as of March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US HoldCo 2, Inc. (the "EMA"). Pursuant to the terms of the EMA, the Medtronic Awards were converted into MMED RSUs based, in part, on (i) the average closing trading price of a Medtronic ordinary share for the last three consecutive trading days ending on March 6, 2026 and (ii) the average closing trading price of a share of MMED common stock for three consecutive trading days starting with and including March 9, 2026 (the "Equity Award Conversion"). Represents the grant of MMED RSUs upon the conversion of certain Medtronic Awards held by the Reporting Person pursuant to the Equity Award Conversion. The MMED RSUs were granted pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan (the "LTIP") and vest in three equal installments on January 26, 2027, January 26, 2028, and January 26, 2029. Includes shares to be issued in connection with the vesting of one or more restricted stock units.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gyurci John
(Last) (First) (Middle)
C/O 18000 DEVONSHIRE STREET
(Street)
NORTHRIDGE CA 91325
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MiniMed Group, Inc. [ MMED ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/11/2026(1)(2) A 15,322(3) A (3) 15,322(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. In connection with MMED's separation from Medtronic plc ("Medtronic") effective March 9, 2026 (the "Separation"), as further described in MMED's current report on Form 8-K filed on March 9, 2026, certain restricted stock units and performance share units granted by Medtronic held by the Reporting Person (the "Medtronic Awards") were converted into time-vesting restricted stock units denominated in shares of MMED's common stock ("MMED RSUs") pursuant to the terms of the Employee Matters Agreement, dated as of March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US HoldCo 2, Inc. (the "EMA").
2. Pursuant to the terms of the EMA, the Medtronic Awards were converted into MMED RSUs based, in part, on (i) the average closing trading price of a Medtronic ordinary share for the last three consecutive trading days ending on March 6, 2026 and (ii) the average closing trading price of a share of MMED common stock for three consecutive trading days starting with and including March 9, 2026 (the "Equity Award Conversion").
3. Represents the grant of MMED RSUs upon the conversion of certain Medtronic Awards held by the Reporting Person pursuant to the Equity Award Conversion. The MMED RSUs were granted pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan (the "LTIP") and vest in three equal installments on January 26, 2027, January 26, 2028, and January 26, 2029.
4. Includes shares to be issued in connection with the vesting of one or more restricted stock units.
Remarks:
Vice President and Chief Accounting Officer
/s/ Bryan F. Kelly, attorney-in-fact 03/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did MiniMed Group (MMED) insider John Gyurci report on this Form 4?

John Gyurci reported receiving 15,322 shares of MiniMed common stock as a grant or award. These represent restricted stock units created by converting his prior Medtronic equity awards following MiniMed’s separation from Medtronic, with no cash purchase involved.

How many MiniMed (MMED) shares did John Gyurci acquire and at what price?

Gyurci acquired 15,322 shares of MiniMed common stock through an equity award, at a reported price of $0.00 per share. This reflects a non-cash conversion of existing Medtronic awards into MiniMed restricted stock units under an employee incentive arrangement.

Why were John Gyurci’s Medtronic awards converted into MiniMed (MMED) RSUs?

His Medtronic restricted stock and performance share units were converted into MiniMed RSUs in connection with MiniMed’s separation from Medtronic. The conversion followed an Employee Matters Agreement that used average trading prices of both companies’ shares around early March 2026.

When do John Gyurci’s MiniMed (MMED) restricted stock units vest?

The MiniMed RSUs vest in three equal installments on January 26, 2027, January 26, 2028, and January 26, 2029. Actual share delivery depends on these vesting dates, aligning the officer’s compensation with the company’s long-term performance.

Is John Gyurci’s MiniMed (MMED) Form 4 transaction an open-market stock purchase?

No, the transaction is not an open-market purchase. It is classified as a grant or award acquisition, reflecting the conversion of existing Medtronic equity awards into MiniMed restricted stock units, with no reported cash paid per share by the insider.

How many MiniMed (MMED) shares does John Gyurci hold after this award?

After the award, Gyurci directly holds 15,322 MiniMed shares. This total includes shares associated with restricted stock units that will be issued as they vest over time, subject to the stated vesting schedule through January 2029.